Business
Palantir and Merck's Q2 Earnings Reports
Tech firm Palantir reported a 16% jump in commercial revenue, driven by strong demand. Meanwhile, pharmaceutical giant Merck adjusted its financial outlook due to charges from an acquisition.
Coverage timeline — 2 articles
CNBC
"Our customers have declined to become vassal states of the language labs," Palantir's co-founder and CEO Alex Karp said after blowout second-quarter earnings.
2026-08-04 10:27 UTC
CNBC
Merck cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals.
2026-08-04 10:34 UTC